Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Esophageal Cancer—An Update Review

View through CrossRef
With the decrease of cancer incidences in a few major cancers, such as breast cancer and lung cancer, the incidence of esophageal cancer has still been climbing up steadily for the past decades, especially adenocarcinoma. Our views on esophageal cancer have been evolving as well. Modifications of the American Joint Committee on Cancer (AJCC) staging has been implemented in its recent edition in 2010. Diagnostic and follow-up standards are changing with more and more physicians and hospitals considering endoscopic ultrasound-guided biopsy as a minimal requirement for definitive diagnosis and accurate staging. In some large centers and by some physicians, laproscopic/ thorascopic biopsy are attempted to diagnose esophageal cancer with more accurate definitive staging. The widespread use of imaging studies, such as computed tomography and/or positon emission tomography, has improved the diagnosis in guiding the therapeutic options. In early stage esophageal cancer management, the acceptable modalities are still radiofrequency ablation, endoscopic mucosal resection, and photodynamic therapy. The advantages and disadvantages are discussed in this article. Surgical resection of early esophageal cancer of T2 or greater staging or N1 is still considered standard with potential to ‘cure’ while minimal invasive laproscopic surgery showed acceptable improved effects and quality of life but are still limited to some tertiary centers. Multi-modality therapies of esophageal cancer in locally advanced stage, both resectable and unresectable, are discussed in this review. For operable diseases, neoadjuvant therapy, peri-surgery therapy, adjuvant therapy, chemotherapy, and/or radiation therapy are discussed. Unresectable esophageal cancer of both adenocarcinoma and squamous cell carcinoma as well as cancer with Her2/neu expression are also considered. The attached table listed the major landmark phase III clinical trials involving esophageal carcinoma. Metastatic cancer management, including the importance of quality of life management among the survivors is also examined.
Title: Esophageal Cancer—An Update Review
Description:
With the decrease of cancer incidences in a few major cancers, such as breast cancer and lung cancer, the incidence of esophageal cancer has still been climbing up steadily for the past decades, especially adenocarcinoma.
Our views on esophageal cancer have been evolving as well.
Modifications of the American Joint Committee on Cancer (AJCC) staging has been implemented in its recent edition in 2010.
Diagnostic and follow-up standards are changing with more and more physicians and hospitals considering endoscopic ultrasound-guided biopsy as a minimal requirement for definitive diagnosis and accurate staging.
In some large centers and by some physicians, laproscopic/ thorascopic biopsy are attempted to diagnose esophageal cancer with more accurate definitive staging.
The widespread use of imaging studies, such as computed tomography and/or positon emission tomography, has improved the diagnosis in guiding the therapeutic options.
In early stage esophageal cancer management, the acceptable modalities are still radiofrequency ablation, endoscopic mucosal resection, and photodynamic therapy.
The advantages and disadvantages are discussed in this article.
Surgical resection of early esophageal cancer of T2 or greater staging or N1 is still considered standard with potential to ‘cure’ while minimal invasive laproscopic surgery showed acceptable improved effects and quality of life but are still limited to some tertiary centers.
Multi-modality therapies of esophageal cancer in locally advanced stage, both resectable and unresectable, are discussed in this review.
For operable diseases, neoadjuvant therapy, peri-surgery therapy, adjuvant therapy, chemotherapy, and/or radiation therapy are discussed.
Unresectable esophageal cancer of both adenocarcinoma and squamous cell carcinoma as well as cancer with Her2/neu expression are also considered.
The attached table listed the major landmark phase III clinical trials involving esophageal carcinoma.
Metastatic cancer management, including the importance of quality of life management among the survivors is also examined.

Related Results

The analysis on Tiam2 for expression in esophageal carcinoma: A descriptive study
The analysis on Tiam2 for expression in esophageal carcinoma: A descriptive study
Rationale: To investigate T lymphoma invasion and metastasis inducing factor 2 (Tiam2) protein for expression in esophageal carcinoma and relationship with clinical fea...
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p
Abstract Rationale Circular RNAs (circRNAs) have been demonstrated to contribute to esophageal cancer progression. CircBCAR3 (hsa_circ_0007624) is p...
Molecular Marker Discovery and effect Evaluation of KRT17 and COL1A1 in Esophageal Cancer Detection
Molecular Marker Discovery and effect Evaluation of KRT17 and COL1A1 in Esophageal Cancer Detection
Abstract Esophageal cancer is one of the malignant tumors in the digestive system. Because the early symptoms of esophageal cancer are occult and lack effective screening o...
Risk Factors for Esophageal Cancer in the Cohort of Nuclear Facility Workers
Risk Factors for Esophageal Cancer in the Cohort of Nuclear Facility Workers
Purpose: To assess the influence of non-radiation factors and occupational radiation exposure on the incidence risk of esophageal cancer in nuclear workers considering various hist...
Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer
Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer
PurposeThe aim was to investigate the advantages of dosiomic and radiomic features over traditional dose-volume histogram (DVH) features for predicting the development of radiation...
ÖZOFAGUS ATREZİLİ YENİDOĞANLARDA ANESTEZİK RİSKLER, MORBİDİTE VE MORTALİTE
ÖZOFAGUS ATREZİLİ YENİDOĞANLARDA ANESTEZİK RİSKLER, MORBİDİTE VE MORTALİTE
Giriş: Özofagus atrezisi (ÖA), özofagusun proksimal ve distal bölümlerinin  bağlantısının olmamasıdır ve 3000-4500 canlı doğumda bir görülür. Özofagus atrezisi ve trakeoözofageal f...

Back to Top